What is a biosimilar and how competitive is the adalimumab biosimilar market?

Biosimilar definition: a biosimilar is a biologic medicine (a large molecule drug made from living cells — proteins like antibodies) that is highly similar to an already-approved reference biologic; biosimilars are analogous to generic drugs but for biologics; because biologics are complex molecules made in living cell cultures, exact replication is impossible — biosimilars must demonstrate highly similar structure and clinical equivalence rather than exact chemical identity; FDA approves biosimilars through an abbreviated approval pathway (no full clinical trial required if structural similarity and clinical equivalence are demonstrated). Adalimumab (Humira) biosimilar market: Humira (adalimumab) was the best-selling drug in history — approximately $20 billion in annual global revenue at peak; AbbVie's Humira patent exclusivity in the U.S. expired in January 2023 (final patents); 8+ adalimumab biosimilars received FDA approval and launched in 2023 (the largest U.S. biosimilar launch ever); AbbVie's own biosimilar (Hadlima) at 5% discount, Amgen's Amjevita, Pfizer's Abrilada, Sandoz's Hyrimoz, Coherus's Yusimry, and others all compete; competition is primarily on price (biosimilars vs. Humira at discounts); insurers and pharmacy benefit managers negotiate significant rebates. Why biosimilar competition is intense: the adalimumab market attracted many biosimilar entrants because of Humira's enormous market size; each biosimilar manufacturer invested $200-500M in development and production; to recover investment, biosimilar makers need market share; winning market share requires price discounts and rebates; this creates severe price competition; the combination of many competitors, complex rebate negotiations, and slow insurance formulary switching compresses margins significantly.

What is a PD-1 checkpoint inhibitor and what is toripalimab approved for?

PD-1 checkpoint inhibitor mechanism: PD-1 (Programmed Death-1) is an immune checkpoint protein on T-cells that, when activated by tumor cells expressing PD-L1 (PD-L1 is the ligand), sends an 'off' signal that prevents T-cells from attacking the tumor; this is a tumor immune evasion mechanism — tumors use PD-L1 expression to 'hide' from the immune system; pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, BMS) are the two dominant approved PD-1 inhibitors that block this interaction, allowing T-cells to recognize and attack tumor cells; these drugs have transformed oncology outcomes in many tumor types. Toripalimab: toripalimab (Loqtorzi is the brand name in the U.S.) is a PD-1 inhibitor developed by Shanghai Junshi Biosciences in China; Coherus licensed U.S. rights from Junshi; toripalimab received FDA approval in October 2023 for nasopharyngeal carcinoma (NPC) — the first PD-1 inhibitor specifically approved for NPC. Nasopharyngeal carcinoma (NPC): NPC is a cancer arising in the nasopharynx (the upper part of the throat behind the nose); it is much more common in Southeast Asia, Southern China, and North Africa than in the U.S. or Europe (associated with Epstein-Barr virus infection); U.S. incidence is approximately 1-2 cases per 100,000 people annually; the small U.S. patient population limits commercial revenue from NPC alone. Broader potential: toripalimab is approved in China for NPC and several other indications (esophageal cancer, melanoma); if Coherus seeks and obtains additional U.S. approvals in tumor types where PD-1 inhibitors are effective (NSCLC, gastric cancer, head and neck cancer), the franchise could expand; however, competition from pembrolizumab and nivolumab (which have broad FDA approvals and commercial infrastructure) is extremely difficult to overcome in most oncology settings.

How do pharmaceutical gross-to-net discounts affect specialty pharma revenue?

Gross-to-net definition: in the U.S. pharmaceutical market, a drug has a 'list price' (WAC — Wholesale Acquisition Cost) — the price before any discounts; however, the actual revenue received by the pharmaceutical company (net revenue) is dramatically less than the list price after subtracting: pharmacy benefit manager (PBM) rebates (the pharmaceutical company pays PBMs to include the drug on formularies; rebates can be 30-70% of list price for competitive categories); government program discounts (Medicaid best price, 340B discounted pricing, Medicare Part D gaps); patient assistance programs (manufacturer copay cards that reduce patient out-of-pocket to make the drug affordable); returns and chargebacks; the difference between list price and net revenue is the 'gross-to-net discount.' Scale and importance: in specialty dermatology (psoriasis, atopic dermatitis), gross-to-net discounts can be 60-75% — a drug listed at $1,000 per prescription may generate only $250-400 in net revenue per prescription; this means reported prescription volume dramatically understates the revenue challenge; a company must generate enormous prescription volume to reach profitability when net revenue is 25-40% of list price; high gross-to-net discounts are the primary reason specialty pharma commercial launches are difficult. For Arcutis: Zoryve's initial gross-to-net discounts have been high (typical for new specialty dermatology products); as formulary coverage improves and patient assistance programs mature, Arcutis must grow prescription volume while managing gross-to-net as a key variable in financial modeling; investors focus heavily on the net revenue per prescription trajectory as a measure of commercial maturity.

brimindinvest.com / compare / arqt-vs-chrsLIVE

ARQT

Arcutis Biotherapeutics, Inc. · Healthcare - Specialty Pharma (Dermatology)

$26.21

+34.41% this month

VERSUS

⟷

COMPARE

CHRS

Coherus BioSciences, Inc. · Healthcare - Specialty Pharma (Biosimilars & Oncology)

$1.48

0.00% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

ARQT

1

CHRS

3

CHRS LEADS 3/5

Comparison scoreboard

CHRS LEADS 3/5

AI Score

ARQT ✓31.6

CHRS 27.5

1Y Return

ARQT +91.73%

CHRS ✓+92.71%

Fwd P/E

ARQT 22.68

CHRS ✓-1.45

Target Up.

ARQT +32.11%

CHRS ✓+427.03%

Op. Margin

ARQT N/A

CHRS N/A

Metrics last refreshed: 6/22/2026

Quick take

ARQT vs CHRS Stock Comparison: AI Score, Valuation, Performance and Upside

ARQT (Arcutis Biotherapeutics) and CHRS (Coherus BioSciences) are both specialty pharmaceutical companies at different stages and in different niches — Arcutis is a commercial dermatology company with three approved non-steroidal Zoryve products for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, while Coherus is transitioning from biosimilars to oncology with Udenyca/Yusimry/Cimerli biosimilars and toripalimab PD-1 inhibitor in nasopharyngeal carcinoma.

ARQT vs CHRS is commercial dermatology company with multiple approved non-steroidal roflumilast products competing against biologics (Arcutis's Zoryve Cream/Foam portfolio for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis — managing gross-to-net discount and biologic competition while scaling toward profitability) versus biosimilar-to-oncology transitioning specialty pharma (Coherus's pegfilgrastim and adalimumab biosimilar revenue base with toripalimab oncology optionality — navigating intense biosimilar price competition and niche oncology market size limitations).

Live analysis · updated 6/22/2026

CHRS holds the edge across 3 of 5 key metrics in this comparison. CHRS leads on both 1-year return (+92.71%) and forward P/E (-1.45x vs 22.68x for ARQT), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for CHRS (+427.03%) than for ARQT (+32.11%).

Normalized 1Y performance

ARQT

CHRS

Recent returns

ARQT

CHRS

Analyst price targets & sentiment

ARQT · 8 analysts

Price target range

analyst low$33.00
analyst high$36.00
analyst mean$34.63
current price$26.21

+32.1% upside to analyst mean

CHRS · 5 analysts

Price target range

analyst low$4.00
analyst high$12.00
analyst mean$7.80
current price$1.48

+427.0% upside to analyst mean

Who should consider this stock?

ARQT may suit investors who:

→Want commercial dermatology exposure through a growing multi-product franchise of non-steroidal topical treatments addressing genuine steroid-avoidance clinical needs
→Believe Arcutis's three approved products create a synergistic dermatology portfolio that a single sales force can efficiently promote to dermatologist customers
→See Zoryve Cream's approval in pediatric atopic dermatitis and plaque psoriasis as expanding the addressable patient population beyond adults to the largest dermatology markets

CHRS may suit investors who:

→Want specialty pharma exposure through a company with established biosimilar revenue providing some commercial baseline while it builds an oncology franchise through toripalimab
→Believe toripalimab has potential beyond nasopharyngeal carcinoma in broader oncology indications that could transform Coherus's revenue trajectory
→See Coherus as a potential acquisition target for a larger pharma company seeking established biosimilar commercial infrastructure or oncology capabilities

Performance & AI score

Metric	ARQT	CHRS
AI score	31.6	27.5
AI rank	#2153	#2477
Latest close	$26.21	$1.48
1M return	+34.41%	0.00%
6M return	-7.52%	+9.63%
1Y return	+91.73%	+92.71%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	ARQT	CHRS
1Y ago	$19.17K (+91.7%) started 2025-06-18	$19.27K (+92.7%) started 2025-06-18
5Y ago	$9.58K (-4.2%) started 2021-06-18	$1.05K (-89.5%) started 2021-06-18
10Y ago	$12.02K (+20.2%) started 2020-01-31	$946.9 (-90.5%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	ARQT	CHRS
Market cap	$3.28B	$228.29M
Trailing P/E	N/A	N/A
Forward P/E	22.68	-1.45
Price/Sales	7.89	4.87
EV/Revenue	7.63	2.47
Analyst target	$34.63	$7.80
Target upside	+32.11%	+427.03%

Growth, profitability & risk

Metric	ARQT	CHRS
Revenue growth	60.10%	62.00%
Earnings growth	N/A	N/A
EPS growth	N/A	N/A
FCF margin	+0.85%	-57.72%
Operating margin	N/A	N/A
Profit margin	-0.57%	397.30%
ROIC proxy	-1.43%	N/A
Return on equity	-1.43%	N/A
Dividend yield	0.00%	0.00%
Beta	1.52	0.96
Debt/equity	60.47	69.16
Current ratio	2.68	1.56
Quick ratio	2.26	1.43

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

ARQT max drawdown37.50%

CHRS max drawdown45.82%

ARQT max wkly drop16.10%

CHRS max wkly drop24.77%

5Y risk snapshot

ARQT max drawdown93.28%

CHRS max drawdown96.47%

ARQT max wkly drop37.92%

CHRS max wkly drop55.96%

10Y risk snapshot

ARQT max drawdown95.02%

CHRS max drawdown97.88%

ARQT max wkly drop37.92%

CHRS max wkly drop55.96%

Performance metrics by period

Period	Metric	ARQT	CHRS
1Y	Growth	+91.73%	+92.71%
	CAGR	+91.82%	+92.79%
	Sharpe ratio	1.33	1.15
	Max drawdown	37.50%	45.82%
	Max daily drop	14.52%	19.90%
	Max wkly drop	16.10%	24.77%
5Y	Growth	-4.17%	-89.54%
	CAGR	-0.85%	-36.34%
	Sharpe ratio	0.28	-0.16
	Max drawdown	93.28%	96.47%
	Max daily drop	18.83%	30.23%
	Max wkly drop	37.92%	55.96%
10Y	Growth	+20.23%	-90.53%
	CAGR	+2.93%	-21.01%
	Sharpe ratio	0.36	-0.00
	Max drawdown	95.02%	97.88%
	Max daily drop	18.83%	30.23%
	Max wkly drop	37.92%	55.96%

Business comparison

Category	ARQT	CHRS
Company	Arcutis Biotherapeutics, Inc.	Coherus BioSciences, Inc.
Sector	Healthcare - Specialty Pharma (Dermatology)	Healthcare - Specialty Pharma (Biosimilars & Oncology)
Industry	N/A	N/A
Core business	Arcutis Biotherapeutics is a commercial dermatology company focused on developing and commercializing treatments for immune-mediated dermatological diseases. Arcutis's products include Zoryve Cream (roflumilast 0.3% cream for plaque psoriasis, adults and children as young as 6 years — FDA approved 2022), Zoryve Foam (roflumilast 0.3% topical foam for seborrheic dermatitis — FDA approved 2023), and Zoryve Cream 0.15% (for mild-to-moderate atopic dermatitis — FDA approved 2023). Roflumilast is a PDE4 inhibitor (phosphodiesterase-4 inhibitor) — a mechanism of action that reduces inflammation by increasing cyclic AMP levels in immune cells; importantly, roflumilast cream is non-steroidal (no corticosteroid risks like skin atrophy) and potentially safer for long-term use.	Coherus BioSciences is a specialty pharma company with FDA-approved biosimilars and an oncology transition strategy. Coherus's products include Udenyca (pegfilgrastim biosimilar for chemotherapy-induced neutropenia, approved 2018 — pegfilgrastim is Amgen's Neulasta), Yusimry (adalimumab biosimilar for autoimmune diseases, approved 2021), and Cimerli (ranibizumab biosimilar for wet AMD and diabetic macular edema, approved 2022). Coherus is also transitioning into oncology through toripalimab (a PD-1 checkpoint inhibitor licensed from Junshi Biosciences/Coherus for U.S. rights) that received approval for nasopharyngeal carcinoma — a niche oncology indication; Coherus also acquired Loqtorzi (toripalimab in combination with chemotherapy) from Junshi for U.S. commercialization.
Investor focus	Investors track Arcutis's net revenue growth across its approved products, gross-to-net discounts (how much of list price is collected after payer rebates and patient assistance), commercial launch execution, and cash burn/path to profitability.	Investors track Coherus's biosimilar revenue (Udenyca market share vs. Neulasta Onpro, Yusimry adalimumab competition), toripalimab oncology launch progress, cash position, and the overall financial performance of a challenging biosimilar transition.

ARQT strengths

→Multiple approved products in dermatology create a growing commercial portfolio — three approved products covering plaque psoriasis, atopic dermatitis, and seborrheic dermatitis build a combined dermatology franchise; multiple products allow a single sales force to address different skin conditions with the same dermatologist customer base
→Steroid-free mechanism (PDE4 inhibition) addresses a genuine patient need in chronic skin diseases — corticosteroids (still the most widely prescribed topical treatment) cause skin thinning and other side effects with long-term use; non-steroidal alternatives are highly valued for chronic conditions requiring continuous treatment
→Roflumilast mechanism is validated by crisaborole (Eucrisa, oral roflumilast approved for COPD) demonstrating tolerability — roflumilast's mechanism (PDE4 inhibition) has proven safety track record in oral form; the topical formulation's local effect reduces systemic exposure and side effects

CHRS strengths

→Biosimilar portfolio provides baseline revenue from established products — Udenyca (pegfilgrastim biosimilar) has a multi-year commercial track record; biosimilars generate stable if competitive revenue from a growing installed patient base
→Toripalimab represents optionality in oncology beyond biosimilars — approval in nasopharyngeal carcinoma (NPC) provides an oncology presence; if toripalimab demonstrates activity in broader oncology indications, the franchise could expand significantly
→Adalimumab biosimilar market is large — Humira (adalimumab) was the best-selling drug in history ($20B+ peak annual revenue); the entry of multiple biosimilars (2023+) is dramatically reducing adalimumab net prices; biosimilar players who gain market share in adalimumab could see meaningful revenue

Risks to watch — ARQT

→Commercial launch is competing against dupilumab (Dupixent) for atopic dermatitis — Dupixent is a blockbuster ($10B+ annual revenue) biologic for atopic dermatitis that is now first-line therapy; topical Zoryve must find its positioning vs. a highly effective biologic
→Gross-to-net discount (GTN) erosion is significant in specialty dermatology — dermatology drugs face substantial rebates and patient copay assistance costs; actual revenue per prescription may be significantly below list price; managing GTN while investing in commercial infrastructure is challenging
→Path to profitability requires scaling revenue while managing cash burn — Arcutis is spending significant cash on commercial infrastructure; achieving profitability requires product revenue to grow faster than commercial costs

Risks to watch — CHRS

→Biosimilar competition is extremely intense — Coherus competes against multiple adalimumab biosimilars from AbbVie (Hadlima), Amgen (Amjevita), Pfizer (Abrilada), Sandoz, and others; price competition is fierce; maintaining market share requires ongoing rebate commitments that compress margins
→Toripalimab oncology positioning is in a niche indication (NPC) with a small U.S. patient population — NPC (nasopharyngeal carcinoma) is relatively rare in the U.S. (more common in Asia); commercial revenue from NPC alone is limited; broader oncology expansion requires additional clinical development
→Strategic direction clarity is needed — Coherus is managing biosimilars (price competition), oncology (clinical and commercial investment), and financial pressure simultaneously; a clearer strategic focus or transaction might be necessary to improve shareholder value

Frequently asked questions

PDE4 mechanism: phosphodiesterase-4 (PDE4) is an enzyme that breaks down cyclic AMP (cAMP), a second messenger molecule in cells; when PDE4 breaks down cAMP, cAMP levels fall; PDE4 inhibitors block this breakdown, causing cAMP levels to increase; elevated intracellular cAMP suppresses the production of pro-inflammatory cytokines (TNF-alpha, IL-12, IL-23, IL-17) in immune cells while increasing anti-inflammatory mediators; this leads to broad anti-inflammatory effects relevant to multiple skin conditions. Why it works in psoriasis and atopic dermatitis: plaque psoriasis is driven by overactive T-cells producing inflammatory cytokines (IL-17, IL-23) that cause abnormal skin cell proliferation; atopic dermatitis (eczema) involves overactive Th2 immune response driving IL-4, IL-13, and IgE-mediated inflammation; PDE4 inhibition suppresses both the Th17 inflammatory pathway (psoriasis) and Th2 pathway (atopic dermatitis), making roflumilast relevant in both conditions. Roflumilast's systemic history: roflumilast was first approved orally (as Daliresp) for COPD (chronic obstructive pulmonary disease) in 2011; its oral use validates the mechanism's safety profile; topical roflumilast cream is a local application that provides skin inflammation control with minimal systemic absorption, addressing dermatology applications with a well-characterized mechanism. Advantages over corticosteroids: topical corticosteroids (hydrocortisone, triamcinolone, betamethasone) are the most prescribed topical treatments for psoriasis and atopic dermatitis; however, long-term use causes skin atrophy (thinning), stretch marks, and systemic absorption concerns; non-steroidal PDE4 inhibitors like roflumilast cream avoid these steroid-related side effects, making them safer for long-term use and for sensitive areas (face, skin folds, genitalia).

AI Prediction SignalNext 5 trading days

Members only

ARQT

+2.8%BUY

CHRS

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides